Markets HRMY

Harmony Biosciences Names Peter Anastasiou CEO

October 12, 2026 — 07:18 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Harmony Biosciences Holdings, Inc. (HRMY), a biopharmaceutical company, on Monday announced that Senior Executive Vice President and Chief Operating Officer Peter Anastasiou will become President and CEO and join the Board, effective January 1, 2027.

CEO Jeffrey Dayno will retire on December 31, after nine years with the company, and step down from the Board of Directors.

The company said Dayno will serve as a non-executive advisor throughout 2027 to support its growth objectives.

The company reiterated its full-year 2026 WAKIX net revenue guidance of $1 billion to $1.04 billion.

The company said it remains on track to report data from the multiple ascending dose study of its BP-205 candidate in the fourth quarter of 2026.

In the pre-market trading, Harmony Biosciences is 3.18% lesser at $39 on the Nasdaq.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
HRMY

Latest Articles
Data is currently not available